Vaxcyte, Inc. — Director's Dealing 2022

May 25, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-05-23

Reporting Person: Sauer Paul (SVP Process Dev, Manufacturing)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-23	Common Stock	S	3000	$26.2235	Disposed	23687	Direct

Footnotes

F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.72 to $26.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Includes 1,562 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 17, 2022.